{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:54:17Z","timestamp":1770512057757,"version":"3.49.0"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T00:00:00Z","timestamp":1406592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>This study aimed to increase the understanding of health resource utilization (HRU) associated with skeletal-related events (SREs) occurring in patients with bone metastases secondary to advanced prostate cancer. A total of 120 patients from Germany, Italy, Spain and the United Kingdom were enrolled in this observational study. They had bone metastases secondary to prostate cancer and had experienced at least one SRE in the 97 days before giving informed consent. HRU data were collected retrospectively for 97 days before enrolment and prospectively for up to 18\u201321 months. HRU, including the number and duration of inpatient hospitalizations, number of outpatient and emergency department visits and procedures, was independently attributed by investigators to an SRE. Of the 222 SREs included in this analysis, 26% were associated with inpatient stays and the mean duration per SRE was 21.4 days (standard deviation (SD) 17.8 days). Overall, 174 SREs (78%) required an outpatient visit and the mean number of visits per SRE was 4.6 (SD 4.6). All SREs are associated with substantial HRU. Preventing SREs in patients with advanced prostate cancer and bone metastases may help to reduce the burden to both patients and European healthcare systems.<\/jats:p>","DOI":"10.3390\/jcm3030883","type":"journal-article","created":{"date-parts":[[2014,7,29]],"date-time":"2014-07-29T10:58:58Z","timestamp":1406631538000},"page":"883-896","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study"],"prefix":"10.3390","volume":"3","author":[{"given":"Amit","family":"Bahl","sequence":"first","affiliation":[{"name":"University Hospitals Bristol, Bristol Royal Infirmary, Upper Maudlin St., Bristol, Avon BS2 8HW, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Hoefeler","sequence":"additional","affiliation":[{"name":"Research Centre Ruhr, Pferdebach Street 30, Witten 58455, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[{"name":"Integrated Cancer Centre Clara Campal (CIOCC), Calle O\u00f1a 10, Madrid 28050, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Hechmati","sequence":"additional","affiliation":[{"name":"Health Economics, Amgen (Europe) GmbH, Dammstrasse 23, Zug 6301, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Garzon-Rodriguez","sequence":"additional","affiliation":[{"name":"Institute of Oncology Catal\u00e1 ICO-IDIBELL, Avenue Gran Via de l'Hospitalet, 199-203,  Hospitalet de Llobregat, Barcelona 08908, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ashcroft","sequence":"additional","affiliation":[{"name":"Pinderfields General Hospital, Mid Yorkshire Hospitals NHS Trust, Wakefield WF1 4DG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Lorusso","sequence":"additional","affiliation":[{"name":"National Cancer Institute IRCCS Giovanni Paolo II, Viale Orazio Flacco 65, 70124, Bari, Italy"},{"name":"Oncology Institute ASL, Via Antonio Miglietta, Lecce 5 73100, Province of Lecce, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prayashi","family":"Ghelani","sequence":"additional","affiliation":[{"name":"Biostatistics, Ovatech Solutions, 112 Morden Road Abbey, London SW19 2NA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Wei","sequence":"additional","affiliation":[{"name":"Biostatistics, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Thomas","sequence":"additional","affiliation":[{"name":"Scientific Publications, Amgen (Europe) GmbH, Dammstrasse 23, 6301 Zug, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"L\u00fcftner","sequence":"additional","affiliation":[{"name":"Charit\u00e9-University Medical Hospital Berlin, Charit\u00e9 Campus Benjamin Franklin, Charit\u00e9platz 1,  Berlin D-10117, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2014,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support. Care Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"DePuy","year":"2007","journal-title":"Support. Care Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"Norgaard","year":"2010","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00520-006-0166-y","article-title":"Pain flare in patients with bone metastases after palliative radiotherapy\u2014A nested randomized control trial","volume":"15","author":"Loblaw","year":"2007","journal-title":"Support. Care Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00402-001-0359-2","article-title":"Surgery of skeletal metastases","volume":"122","author":"Katzer","year":"2002","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0959-8049(97)10128-9","article-title":"Bone metastases\u2014The clinical problem","volume":"34","author":"Rubens","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"ref_11","unstructured":"Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C., and Parkin, D.M. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Available online:http:\/\/globocan.iarc.fr."},{"key":"ref_12","first-page":"341","article-title":"Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice","volume":"4","author":"Delea","year":"2006","journal-title":"J. Support. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/pcan.2012.42","article-title":"Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases","volume":"16","author":"Hagiwara","year":"2013","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_14","first-page":"317","article-title":"The cost of treating skeletal-related events in patients with prostate cancer","volume":"14","author":"Lage","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: A French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jval.2010.11.014","article-title":"Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: Estimation for the Portuguese National Health System","volume":"14","author":"Felix","year":"2011","journal-title":"Value Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2354.2009.01135.x","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur. J. Cancer Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3111\/13696998.2013.779921","article-title":"Cost of skeletal-related events in European patients with solid tumours and bone metastases: Data from a prospective multinational observational study","volume":"16","author":"Hechmati","year":"2013","journal-title":"J. Med. Econ."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","article-title":"How should cost data in pragmatic randomised trials be analysed?","volume":"320","author":"Thompson","year":"2000","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gunther, O., Body, J.J., Sleeboom, H., Hechmati, G., Pereira, J., Maniadakis, N., Terpos, E., Acklin, Y.P., Finek, J., and Mossman, T. (2011). Health resource utilisation (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BMS): Results from a retrospective, multinational European study. Value Health, 14.","DOI":"10.1016\/j.jval.2011.08.1218"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urolonc.2005.06.020","article-title":"Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis","volume":"24","author":"Saad","year":"2006","journal-title":"Urol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Exp\u00f3sito, J., Jaen, J., Alonso, E., and Tovar, I. (2012). Use of palliative radiotherapy in brain and bone metastases (VARA II study). Radiat. Oncol., 7.","DOI":"10.1186\/1748-717X-7-131"},{"key":"ref_25","unstructured":"Single fraction radiotherapy for bone metastases (updated 2007). Available online:http:\/\/www.rcr.ac.uk\/docs\/oncology\/pdf\/bonemetsreport.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clon.2007.03.011","article-title":"Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005","volume":"19","author":"Williams","year":"2007","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/pcan.2009.50","article-title":"Bone health and prostate cancer","volume":"13","author":"Saylor","year":"2010","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_28","unstructured":"Xgeva (Denosumab) Summary of Product Characteristics (updated 03\/01\/2014). Available online:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/3\/3\/883\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:14:10Z","timestamp":1760217250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/3\/3\/883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,29]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,9]]}},"alternative-id":["jcm3030883"],"URL":"https:\/\/doi.org\/10.3390\/jcm3030883","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,29]]}}}